Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sess
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Avis Budget Group Inc (NASDAQ: CAR ) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results. Avis Budget reported quarterly earnings of 98 cents per share which missed the analyst consensus estimate of $1.80 per share. The company reported quarterly sales of $2.998 billion which missed the analyst consensus estimate of $3.101 billion. Avis Budget Group shares dipped 13.3% to $144.20 in pre-market trading. Here are some other stocks moving lower in pre-market trading. Fiverr International Ltd (NYSE: FVRR ) shares dipped 16.4% to $9.69 in pre-market trading following weak second-quarter results. Costar Group Inc (NASDAQ: CSGP ) declined 14.2% to $26.01 in pre-market trading after the company reported mixed second-quarter...
S. 1% on Wednesday. Shares of Avis Budget Group Inc (NASDAQ: CAR ) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results. 80 per share.
101 billion. 20 in pre-market trading. Here are some other stocks moving lower in pre-market trading. 69 in pre-market trading following weak second-quarter results.
01 in pre-market trading after the company reported mixed second-quarter financial results and cut its FY26 sales guidance below estimates. 81 in pre-market trading after the company reported worse-than-expected second-quarter financial results. 78 in pre-market trading after surging 24% on Tuesday. 90 in pre-market trading after the company reported first-quarter financial results and issued second-quarter sales guidance below estimates.
90 in pre-market trading after the company reported third-quarter financial results and issued weak fourth-quarter adjusted EPS guidance. 72 in pre-market trading after the company announced it received communication from the FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form. 50 in pre-market trading as the company announced the pricing of public offering. 80 in pre-market trading following fourth-quarter results.
66 in pre-market trading. Photo via Shutterstock